The incidence of childhood obesity is on the rise, with recent data from the Centers for Disease Control and Prevention suggesting that 12-18% of children aged 2-19 years are considered obese. This represents a three- to sixfold increase in the prevalence of pediatric obesity since the 1970s. Obesity has clear complications and comorbidities, including increased risk of type 2 diabetes, asthma, and nonalcoholic fatty liver disease, as well as an increased risk of adverse psychological issues such as depression. Characteristics that increase the risk for pediatric obesity include male gender, advancing age (adolescents are at high risk), and minority status.

In 2005, the U.S. Preventive Services Task Force released a recommendation statement promoting the use of body mass index (BMI) as a screening method for obesity in the pediatric population. Recently, the USPSTF released an updated statement on pediatric obesity with a stronger focus on treatment and outcomes.

**Screening**

Screening for overweight and obese children should be performed utilizing BMI, which is calculated as weight in kilograms divided by height in meters squared. This is a grade “B” recommendation, meaning that there is a moderate degree of certainty that the net benefit is moderate. The BMI is then plotted on growth charts against gender- and age-specific norms. These growth charts were published by the CDC in 2000 and were formulated with data from multiple national health examination surveys spanning 3 decades.

In the pediatric population, “overweight” is defined as BMI in the 85th-94th percentiles; “obese” is defined as a BMI of at least the 95th percentile, as plotted for age and sex, based on data collected from 1963 to 1995. Although the USPSTF found moderate evidence to utilize BMI an acceptable screening method for obesity, it did not find adequate evidence to recommend screening timing and intervals other than routine measurements performed at regularly scheduled health maintenance visits. The USPSTF also found sufficient evidence to recommend initiation of screening for obesity beginning at 6 years of age.

**Behavioral Treatment**

On review of thirteen trials including more than 1,200 children and adolescents aged 4-18 years, the USPSTF found moderate evidence that identification of an obese pediatric patient via BMI screening with subsequent referral to a moderate- to high-intensity intervention at a specialty health care center resulted in modest weight loss over 12 months; these programs were defined as providing at least 25 hours of contact between the child and/or family and the health care center over a 6-month period. Very low or low-intensity programs (defined as less than 25 hours of patient to health professional interaction over a 6-month period) were not found to be statistically significant in terms of weight loss.

Interventions were deemed comprehensive if they included the following characteristics: weight loss/diet counseling, physical activity counseling, behavior management instruction, and sustained support regarding new diet and exercise changes. Behavioral management often included cognitive behavioral therapy in reference to self-monitoring, impulse control, and triggers for overeating/poor food choices.

Examples of moderate weight loss in a 16-year-old were, on average, 19 pounds for a female and 22-23 pounds for a male.

There was limited evidence that moderate- to high-intensity programs yielded improvements in insulin resistance in pediatric patients. However, there was not a consistent reduction in other cardiovascular risk factors, including blood pressure or cholesterol levels.

**Pharmacologic Treatment**

Two medications are FDA-approved for weight reduction in the adolescent population. Orlistat is a pancreatic lipase inhibitor and is approved for children 12 years and older; sibutramine is a centrally acting appetite suppressant and serotonin reuptake inhibitor approved for adolescents 16 years and older. Small but significant improvements in BMI were seen with these medications; however, they were used in conjunction with behavioral interventions.

While the addition of either of the two medications did not appear to affect growth or mental health, gastrointestinal side effects—such as abdominal cramping, flatulence, or oily spotting—were common and found in about 30% of the patient population, particularly with sibutramine. Sibutramine also has been associated with an increase in blood pressure and heart rate, with recent questions linked to increased cardiovascular events in the adult population. Cardiovascular effects in the pediatric population are unknown.

Data also are lacking regarding weight maintenance in the pediatric population after discontinuation of these medications.

**ADHD in Young Adults Linked to Increased Obesity Risk**

**BY MITCHEL L. ZOLER**

**From the 11th International Congress on Obesity**

Stockholm — Young adults with hyperactive-impulsive symptoms of attention-deficit/ hyperactivity disorder had a significantly increased risk for obesity in a U.S. national sample of nearly 12,000 people.

“This is the first population-based study to examine the association between ADHD symptoms as dimensional predictors of adult BMI [body mass index], changes in BMI, and risk of adult obesity and hypertension,” Bernard F. Fuemmeler, Ph.D., and Mackenzie Mady, D.O., of Geisinger Health System in Orwigsburg, Pa., said in their poster at the meeting. “Our findings show a dose-response increase in risk of obesity associated with increasing ADHD symptoms, especially hyperactive-impulsive symptoms.”

Based on these findings, “it may be clinically relevant to screen patients with ADHD who are at risk for obesity to develop appropriate treatment strategies,” suggested Dr. Fuemmeler, a clinical psychologist at Duke University in Durham, N.C. “The effectiveness of obesity treatment may be diminished, and relapse may be greater among those with more ADHD symptoms.” he added.

The biologic plausibility of a link between ADHD symptoms and obesity is based on results from position emission tomography studies showing a reduced availability of dopamine receptors in people with ADHD and in people who are obese. Better understanding of the link may improve understanding of the etiology of obesity and may help identify biomarkers of obesity.

Dr. Fuemmeler and his coinvestigators used data from the fourth wave of the National Longitudinal Study of Adolescent Health, a recurring national survey begun in 1994 sponsored by the National Institute of Child Health and Human Development and several other branches of the National Institutes of Health.

At onset, the representative sample of adolescents in the survey had an average age of 16. The fourth round of longitudinal data collection occurred in 2007 and 2008 at an average age of 29, and included 11,666 people, 49% women; among the sample, 66% were white, 15% African American, 12% Hispanic, and 7% other.

Average BMI for the entire sample was 29 kg·m⁻². In all, 37% of participants were obese (BMI of 30 kg·m⁻² or greater); 33% were normal weight (BMI less than 25 kg·m⁻²); and 30% were overweight (BMI 25-29 kg·m⁻²).

Hypertension prevalence in the entire group was 13%.

In a multivariate analysis that controlled for age, sex, race, ethnicity, education, depression, alcohol use, smoking, and physical activity, survey participants with hyperactive-impulsive symptoms of ADHD had a statistically significant 63% increased risk of being obese compared with survey participants without these symptoms. People with ADHD symptoms of inattention had a smaller increased obesity risk, 23%. The data showed the link between ADHD symptoms and hypertension was weaker than the link between ADHD and obesity.

Although even people with one hyperactive-impulsive symptom had a modestly increased obesity risk, the risk was highest among people with three to eight hyperactive-impulsive symptoms, which linked with a 50% increased risk in the multivariate analysis. In contrast, people with inattentive symptoms showed an increased obesity risk in only those with three to nine symptoms, a 21% increased risk.

Analysis of longitudinal data, collected at four times during the course of the survey to date showed hyperactive-impulsive symptoms linked with increasing BMI over the course of adolescence and into adulthood.